

Impact of Opiate Abuse and Addiction on Families / Child Welfare / Pregnancy

Ted Parran Jr. MD FACP
Isabel and Carter Wang Professor and Chair in Medical Education
CWRU School of Medicine
Cleveland, Ohio
tvp@case.edu

Substance Abuse or At Risk Use

- Planned use to intoxication/disinhibition
- Rare adverse consequences
- Use remains within peer group norms
- “Willful misconduct”

Chemical Dependence: UCR

- The **intermittent** **inconsistent** **repetitive** **loss of control** over the use of euphoria producing drug (EPD), resulting in **repetitive adverse consequences**.
- EPD's:
 - **Opioids**
 - Stimulants (including nicotine)
 - Sedative-hypnotics
 - Cannabinoids
 - Other


Recognizing Addiction

- DSM-5 Criteria for Substance Use Disorder¹
 - Tolerance
 - Withdrawal
 - Taken more/longer than intended
 - Desire/unsuccessful efforts to quit use
 - Great deal of time taken by activities involved in use
 - Use despite knowledge of problems associated with use
 - Important activities given up because of use
 - Recurrent use resulting in a failure to fulfill important role obligations
 - Recurrent use resulting in physically hazardous behavior (eg, driving)
 - Continued use despite recurrent social problems associated with use
 - Craving for the substance


≥ 2 items → Dx

≥ 6 items → severe
case

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth edition*. Arlington, VA: American Psychiatric Publishing(2013).



Activation of the reward pathway by addictive drugs



Addiction as a Familial Disorder

- Aristotle- “drunken women bring forth children like themselves”
- Plutarch- “one drunk begets another”
- Every study since the late 1800’s shows higher rates of addiction in relatives of alcoholics.
- 3 to 4 times higher rate in first degree relatives.

From Familial to Genetic

“genes vs. environment”

- What is the relative importance of genetic influences (**nature**) compared to environmental and family influences (**nurture**)?
 - Adoption studies = **genes matter**
 - Twin studies = **environment matters**
- 50-60% genetic, 20% environment, 20% ???

Chemical Dependence: prevalence

- 13.5% lifetime prevalence
- **Lower in older / same in younger women**
- 15–18% primary care outpatient
- 25% primary care inpatient
- 40% trauma inpatient
- 40–70% psychiatric inpatient
- **25% of couples bearing children (1/4)**
- **10-15% tox positive in OB private office / public clinic**

Chemical Dependence: risk factors

- (–) Family history = 0.3 – 3% risk
- (+) One parent = 20% risk
- (+) Two parents = 30% risk

- **NOT**
 - ***WOMEN < MEN (IF BORN AFTER 1950)***
 - ***WEALTHY < POOR***
 - ***WHITE < “MINORITIES”***

Chemical Dependence: Natural History (It's a Brain Disease)

- Brain function number 3: Behavior Control
- Diseases of the brain that effect Behavior Control Centers:
 - Addiction, Schizophrenia, Bipolar
- Sns/Sx of the **biologic** disease of addiction:
 - Behavioral, Behavioral, Behavioral ...
- Not a psychological disease

Addiction v. Axis III: natural history

- Increased dysfunction and disability in the following domains:

<u>ADDICTION</u>		<u>AXIS III</u>
1. Self image*	v.	Physical
2. Interpersonal*	v.	Work
3. Social*	v.	Financial
4. Financial*	v.	Social
5. Legal *	v.	(nothing)
6. Work	v.	Interpersonal
7. Physical	v.	Self image

*** = very problematic in pregnancy / child raising**

Addiction morbidity and mortality: the unspeakable toll

- Tobacco addiction kills 33%, maims 33%.
- Other addictions-
 - ***divorce, *domestic violence, *child abuse, *child neglect** (**very** common with opioids)
 - ***suicide, *trauma**
 - productivity, disability
 - medical complications
 - *very problematic in pregnancy/child rearing

Treating Addictions as chronic illnesses- the challenge

- Study the natural history
- Implement screening strategies (CRAFFT / AUDIT-C)
- Practice presenting the diagnosis (SOAPE)
- Assess patient's readiness for change
- Negotiate treatment plans
- Develop comfort with pharmacotherapy
- Strategies for long-term monitoring

CRAFFT

C Have you ever ridden in a **CAR** driven by someone (including yourself) who was high or had been using alcohol or drugs?

R Do you ever use alcohol or drugs to **RELAX**, feel better about yourself?

A Do you ever use alcohol or drugs while you are by yourself **ALONE**?

F Do you ever **FORGET** things you did while using alcohol or drugs?

F Do your **FAMILY** or **FRIENDS** ever tell you that you should CUT down on your drinking or drug use?

T Have you ever gotten into **TROUBLE** while you were using alcohol or drugs?

Score: **2 or more yes** answers indicate a problem for follow-up.


(Knight et al., 1999)

Presenting the Diagnosis: the Brief Intervention (cont.)

- “Pearls to use” - **SOAPE**
 - **S**upport (“I want to work with you”)
 - **O**ptimism (“you can and will get better”)
 - **A**bsolution (“it is not your fault for having the illness, just your responsibility to manage it”)
 - **P**lan (depends on the patient readiness for change)
 - **E**xplanatory model (“this can be hard to hear, what are your thoughts about your substance use?”)

Presenting the Diagnosis

Assessing Readiness




Motivational interviewing in a nut shell

- Pre-contemplative: maintain the relationship, encourage change, ?mobilize consequences
- Contemplative: educate ... educate ... educate
- Preparation / Action: behavioral change, monitor ... support ... monitor ... support ...
monitor ... support

Opioid Addiction: Specifics

Natural HX of Opioid Addiction: 40 year longitudinal experience



The Natural History of Opioid Addiction

- High mortality rate
- High incarceration rate
- High relapse rate

BUT ALSO ...

- More than 50% eventual “sobriety” rate (if you include stable OMT with abstinent as “sober”)

SO THE GOAL IS ...

- Keep them alive, increase sobriety and decrease relapse!

MAT (medication assisted treatment)

- Why Do It? (re: the patient)
 - It decreases relapse
 - It decreases re-incarceration
 - It decreases death rates
 - ... SO IT IMPROVES LIVES
- Why Do It? (re: the provider)
 - IF MAT does all of the above ... then it makes dealing with patients / families easier / more efficient / more effective (**AND** more enjoyable).

MAT: 2 Approaches

- Harm Reduction:
 - Pharmacotherapy first ??? Addiction TX second
 - E.g. historical methadone maintenance experience
 - E.g. “stand alone Suboxone”
- Adjunct to or Addition to Treatment:
 - Treatment first
 - Then add in MAT to try to improve outcomes
 - E.g. Intensive Outpatient Counseling & 12 step meeting attendance ... plus MAT
- For the Child Protective Services clients ...
AVOID HARM REDUCTION MODEL ...
REQUIRE ADJUNCT TO TX MODEL


MAT with opioid dependence: What Are The Medications???

- **Methadone**: “opioid maintenance TX”
 - ONLY if part of a Methadone Treatment Program
- **Buprenorphine**: “opioid maintenance TX”
 - **Not** harm reduction (as above)
- **Naltrexone**: “opioid blocker treatment”
 - Pills (naltrexone) or Shots (Vivitrol)
- OUTCOMES? ... *SIMILAR!* (**if** done well)

MAT maintenance: outcome data

- Opiate maintenance therapy (methadone OR buprenorphine) on balance results in improvement in every domain of life function ... especially if combined with good treatment:
 - family
 - health
 - legal
 - employment
 - financial

Relapse rates



Opioid maintenance data

- Duration of therapy -
 - When should people get off?
 - Longer = better.
 - > 1.5 years better than < 1.5 years.
- Need for comprehensive longitudinal gradual approach.
- Need ultimate goal of abstinence.
- *Methadone OR Subutex in pregnancy.*

Opiate maintenance - methadone

- What's a “GOOD” methadone program?
 - Release of information for all health care / social service / legal providers ... with frequent contact
 - Tox screening monthly or more often – results avail.
 - Counseling
 - Open TX Plan ... harm reduction **OR** abstinence
 - The treatment goal should be CLEAR (and shared)
 - Dose \leq 120mg/d
 - Discourage other controlled RX drugs (benzos etc.)
 - Increasing intensity of treatment over time if non-adherent (problem urines due to still using)

Opiate maintenance - buprenorphine

- What's a “GOOD” buprenorphine program?
 - Release of information for all health care / social service / legal providers ... with frequent contact
 - Tox screening / Counseling / OARRS required
 - Dose \leq 16mg/d ... **most** patients on 4-12mg/d
 - Requires ***combined*** bup-naloxone product mostly
 - NO other controlled RX drugs (benzos etc.)
 - Increasing intensity of treatment over time if non-adherent (problem urines due to still using)
 - Accepts insurance payments for visits

Monitoring Opioid Dependent Pts.

- Constant awareness of client's level of participation in Tx. Prog. (releases!!!!!!!!!!!!!!)
- Ask Tx. Prog. about patient's OARRS result / tox screen result / continued use of MAT.
- Obtain patient and collateral report of sobriety and **full** adherence with the treatment plan.
- 12 Step Monitoring – DO IT!
 - Ask client AND sponsor: how often / which meetings / what “step” working on ... PLUS signed slips.
- **ANY** slip in adherence = increased relapse risk!!!!

In conclusion ...

- Addictive disease is prevalent in men and women of child rearing age.
- Onset late adolescence / young adulthood
- Peak activity during the “child bearing” years
- Addiction = loss of control ... in many ways
- Symptoms are behavioral & disastrous
- General Addiction – Child Welfare Risks
- Opioid Addiction:
 - Some specific risks (child neglect, overdoses)
 - Some specific TX options (TX plus MAT)